Aerie Pharmaceuticals (Aerie Pharmaceuticals) Change In Inventory : $-15.2 Mil (TTM As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Change In Inventory?

Aerie Pharmaceuticals's change in inventory for the quarter that ended in Sep. 2022 was $0.5 Mil. It means Aerie Pharmaceuticals's inventory declined by $0.5 Mil from Jun. 2022 to Sep. 2022 .

Aerie Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2021 was $-12.1 Mil. It means Aerie Pharmaceuticals's inventory increased by $12.1 Mil from Dec. 2020 to Dec. 2021 .

Aerie Pharmaceuticals's Total Inventories for the quarter that ended in Sep. 2022 was $46.8 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Aerie Pharmaceuticals's Days Inventory for the quarter that ended in Sep. 2022 was 617.44.

Inventory Turnover measures how fast the company turns over its inventory within a year. Aerie Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.15.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Aerie Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 1.30.

Aerie Pharmaceuticals Change In Inventory Historical Data

The historical data trend for Aerie Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals Change In Inventory Chart

Aerie Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Inventory

Get a 7-Day Free Trial

-9.69

-10.26

-5.17

-12.10

Aerie Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Inventory	Get a 7-Day Free Trial															0.69	-9.62	0.54	-6.56	0.48

Aerie Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.2 Mil.

Aerie Pharmaceuticals (NAS:AERI) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Aerie Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	46.8845	/	6.929	*	365 / 4
	=	617.44

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Aerie Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	6.929	/	46.8845
	=	0.15

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Aerie Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	46.8845	/	36.129
	=	1.30

Aerie Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703

Website

https://www.aeriepharma.com

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

Executives

Peter Frederick Lang	officer: Chief Financial Officer	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan	director, officer: Chief Executive Officer	C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese	officer: Vice President of Finance	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley	officer: CHRO & VP, Corp Services	15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten	officer: Interim CFO	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski	officer: Chief Scientific Officer	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell	director	2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle	director	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander	officer: Chief R&D Officer	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino	officer: Chief Financial Officer
Vicente Jr Anido	director, officer: Chief Executive Officer	1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro	officer: President and COO	15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618